NEW YORK (GenomeWeb News) – Roche said today that it will provide researchers at the University of California, Los Angeles with a range of its genomics tools in a new collaboration to study stem cells and cancer and to develop new targets and biomarkers for disease diagnostics and therapeutics.
Under the agreement, Roche will provide microarray systems from Roche NimbleGen, high-throughput screening tools, genetic expression profilers, and exome sequencing technologies to UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the Jonsson Comprehensive Cancer Center.
Roche also will provide UCLA with reagents and technology and bioinformatics support for developing new predictive biomarkers. The firm's scientists also will work collaboratively with the university to develop new tools for both academic and commercial use.
"By working together at an early stage, we can optimize the technologies and provide the necessary support to improve detection and analysis, and ultimately, the success rate of biomarker discovery," Robert Yates, Head of Roche Applied Science, said in a statement.
"Discoveries made by UCLA scientists while working with the technologies will help provide Roche scientists with insight on academic research and can be used to refine Roche operations or develop new applications for the equipment," added Michael Teitell, a Broad and Jonsson center researcher.